As the initiators of adaptive immune responses, dendritic cells (DCs) are known as the most potent antigen-presenting cells (APCs) to cross-present tumor-associated antigens (TAAs) and prime tumor antigen-specific CD8 T cells (termed cross-priming) to control tumor growth [1,2]. Here, CD8A is linked to neoplasm.